Meropenem is a carbapenem antibiotic that appears to be widely distributed in tissues and is eliminated by both excretion and metabolism. Approximately 70% of meropenem is excreted via the kidneys, thus dosage adjustments are required for patients with renal impairment. The pharmacokinetic parameters for meropenem are similar to those for imipenem/cilastatin, with the exception of meropenem's smaller volume of distribution. The urinary recovery of meropenem is as high as that of imipenem in combination with cilastatin, an inhibitor of renal dehydropeptidase. Therefore, unlike imipenem, meropenem can be used without dehydropeptidase inhibitors to obtain a consistently high concentration in the urine without nephrotoxic effects.
When the pharmacokinetics of meropenem administered either as an iv infusion over 30 minutes or as an iv injection over 5 minutes were compared [17] , peak plasma concentrations of meropenem were doubled during the first hour of dosing after the injection. After 1 hour, the plasma concentrations of meropenem were similar for both routes of administration. The higher initial concentration with the iv injection was not associated with any increased intolerance by the patients. The area under the curve (AUC) values obtained for both routes of administration were not significantly different.
The half-life of an im injection of meropenem is slightly longer than that of an iv administration of meropenem. This longer half-life may be related to delayed absorption rather than to a truly prolonged elimination rate. The peak concentration occurs between 10 minutes and 2 hours after im administration, and the concentration is about one-half of that after iv infusion and one-fifth of that after iv injection. Differences in AUC were also found after patients with lower respiratory tract infections had received 10 doses [17] . A slight accumulation of meropenem with an AUC ratio of 1.18 was found in patients receiving im meropenem. None of this evidence of accumulation is of clinical importance.
Distribution and Tissue Penetration
Meropenem appears to be widely distributed in tissues, with the steady-state volume of distribution in healthy adult volunteers ranging from 12.5 to 20.7 L [18] [19] [20] [21] [22] [23] . The relatively large volume of distribution suggests that the tissue penetration of meropenem is good. The extent of protein binding is very low (2%; unpublished data, Zeneca Pharmaceuticals).
In animal studies, it was shown that meropenem is widely distributed to most organs, with the highest concentrations achieved in the kidney, blood, and urine [23] . Drug concentrations in the liver, lung, skin, uterus, ovaries, rectum, prostate, thyroid, trachea, and lymph nodes were approximately onehalf of the plasma concentration. However, very small concentrations of meropenem were found in the brain and CSF. It also appears that meropenem is able to cross the placenta in rats, although embryo concentrations of the drug were very low compared with maternal blood levels.
The intraperitoneal penetration of meropenem in patients undergoing elective gastrointestinal surgery was examined by Hextall et al. [24] . They found that the peritoneal level of meropenem was 95% of the plasma level. The half-life of meropenem in the peritoneum was similar to the half-life of meropenem in plasma (-1.5 hours). Within the first 2 hours of administration, a peritoneal level as high as 71.95 mg/L (mean, 26.7 mg/L) was found.
The penetration of a single 1-g dose of meropenem into the bile in patients undergoing endoscopic retrograde cholangiography was examined [25] . At the time of endoscopic retrograde cholangiography, the time of which ranged from 61 to 203 minutes after the dose, bile concentrations ranging between 0.7 and 25.7 mg/L (mean, 11.1 mg/L) were found. All concentrations exceeded the MIC50 and MIC90 values for the most common biliary tract pathogens except Enterococcus faecalis. For patients without biliary obstruction, there was no correlation between bile concentration and the time (up to 3.5 hours) after the dose. However, in patients with biliary obstruction, there was a significant increase in bile concentration as the time after the dose increased.
Although bile concentrations of meropenem were significantly lower in patients with biliary obstruction than in patients without biliary obstruction, they remained in the therapeutic range for most biliary tract pathogens. The investigators postulated that the liver is able to secrete meropenem into the bile in both normal and obstructed biliary trees since there is a close correlation between the bile:plasma ratio and time.
The concentration of meropenem in bronchial secretions from patients undergoing fiberoptic bronchoscopy was determined; Bergogne-Berezin et al. [26] found that when patients were given 1 g of meropenem, meropenem concentrations in bronchial secretions reached 20% of serum levels, a level sufficient to eradicate most respiratory pathogens. Therapeutic levels were attained 1 hour after the dose, reaching a mean level of 0.46 mg/L. Slightly higher levels (0.53 mg/L) were found 3 hours after the dose. The concentrations achieved were well above the MICs for most respiratory pathogens.
Clinical studies of meropenem penetration into the skin have been conducted by Wise et al. [18] , Mouton and Michel [27] , Yoshida et al. [28] , and Nichols et al. [4] . The penetration of meropenem into a chemically induced inflammatory exudate was examined by Wise et al. [18] . Patients received a single 1-g dose via iv injection. Meropenem had excellent and rapid penetration into the exudate, with a concentration that was 111% of the plasma concentration. The mean maximal concentration (Cmax) of meropenem in the exudate (28.3 mg/L) was obtained rapidly (at 0.5 hour in one-half of the subjects and at 1.0 hour in the remainder of the subjects). The half-life of meropenem in inflammatory fluid was the same as that in plasma.
Mouton and Michel [27] examined meropenem penetration into suction blister fluid. Subjects received either a regimen of intermittent infusions of meropenem (10 mg/kg every 6 hours iv for three doses) or a regimen of a continuous infusion of meropenem (loading dose of 0.2 mg/kg and 30 mg/kg over 18 hours). Meropenem displayed rapid and sufficient penetration into blister fluid. The blister fluid concentrations of meropenem were 84.7% and 87.1% of the serum concentrations with intermittent administration and continuous infusion, respectively, thereby indicating comparable penetration between the two regimens.
The penetration of meropenem into the skin of rats with third-degree burns was studied by Yoshida et al. [28] . They found that meropenem penetrated burned skin better than normal skin, thus suggesting that meropenem may be a useful agent in the treatment of burn wound infections in humans.
Nevertheless, extrapolations from rats to humans in this regard are tenuous until corroborating data are obtained. In a clinical study, Nichols et al. [4] demonstrated that 500 mg of iv meropenem every 8 hours was as effective as 500 mg of iv imipenem/cilastatin every 6 hours in treating patients with community-acquired skin and soft-tissue infections, such as abscesses, cellulitis, infected ulcers, and infected amputation sites. These studies suggest that meropenem's ability to penetrate into the skin is good.
The uptake of meropenem into human macrophages was examined by Cuffini et al. [29] . These investigators found that meropenem penetrated into human macrophages and remained active. The cellular-to-extracellular concentration ratios were high (range, 3-12). They also found that meropenem reduced the survival of intracellular Staphylococcus aureus.
Metabolism
Meropenem is a 10-methylcarbapenem antibiotic (figure 1). The 10-methyl substitution on the carbapenem ring confers relative stability against renal dehydropeptidase-I (DHP-I) as compared with other penem and carbapenem compounds [1, 30] . Fukasawa et al. [31] . found meropenem to be four times more resistant to DHP-I than imipenem. In vitro, treating meropenem with DHP-I produces a /3-lactam ring-opened product, which exists as a mixture of 1-pyrroline and 2-pyrroline isomers. The same metabolite is produced by chemical hydrolysis under both acidic (pH, < 2) and alkaline (pH, > 13) conditions [30] .
Harrison et al. [19] studied the metabolism of 14 C-labeled meropenem and detected only one metabolite in the urine, the ring-open lactam. Metabolism of meropenem is responsible for between 19% and 27% (table 1) of the plasma clearance of the drug [19, 22, 23] . The ring-open lactam can be produced by three mechanisms: chemical hydrolysis, extrarenal metabolism, and renal metabolism via DHP-I. Chemical hydrolysis occurs under simulated physiological conditions in vitro at 37°C, thus resulting in meropenem half-lives of 11 hours in plasma and 8 hours in urine [20] .
The extrarenal metabolism or degradation of meropenem was suggested by Christensson et al. [34] . Patients with end- stage renal disease and a patient who underwent bilateral nephrectomy were found to have metabolites in their plasma. Since these types of patients have virtually no renal clearance, it was concluded that meropenem undergoes extrarenal metabolism or degradation. Meropenem also undergoes renal metabolism. Burman et al. [22] found that while the average AUC for the metabolite in plasma was 10% of that for meropenem, the average AUC for the metabolite in urine was 20% of that for meropenem.
The degree of metabolism of the carbapenems by DHP-I is a major characteristic by which meropenem differs from imipenem. Imipenem must be combined with cilastatin, an inhibitor of renal dehydropeptidase, to attain sufficient serum and tissue levels of imipenem for antimicrobial activity. The chemical stability of meropenem against DHP-I allows for it to be administered in the absence of a dehydropeptidase inhibitor and to maintain a metabolism profile similar to that of imipenem/cilastatin [22] .
In one study, Burman et al. [22] found that subjects who metabolize imipenem at a high rate also tend to metabolize meropenem at a high rate. In another study, Nilsson-Ehle et al. [21] gave iv infusions of 1 g of meropenem and 1 g of imipenem/cilastatin to healthy males on two separate occasions; they found no differences in the pharmacokinetic parameters of the two drugs with the exception of the volume of distribution (12.5 L for meropenem vs. 14.4 L for imipenem). For both drugs, metabolism accounted for -25% of the total clearance, while urinary recovery of both parent drugs was about 75% of the administered dose.
These results clearly demonstrate that meropenem's stability is comparable with that of imipenem/cilastatin against degradation by renal enzymes. These results also show that there is no need to combine meropenem with a dehydropeptidase inhibitor to achieve high urinary concentrations of meropenem.
Imipenem is administered with cilastatin to reduce the nephrotoxic effects caused by its metabolite as well as to inhibit degradation by DHP-I [35] . High doses of imipenem alone have been shown to cause necrosis of the proximal convoluted tubule in animal studies [36, 37] ; this nephrotoxic effect was found to be completely eliminated when imipenem was given with an equal amount of cilastatin. In contrast, the evaluation of nephrotoxic effects in animals, including rats, rabbits, and cynomolgi, suggests that meropenem and its metabolite have a low nephrotoxic potential [38] .
Excretion
Meropenem displays linear pharmacokinetics over the 250-to 1,000-mg dosing range [20] , with an elimination half-life of NOTE. AUC = area under the curve; Gma,, = maximal concentration of drug; Cl, = renal clearance; C1 T = total plasma meropenem clearance; fe = fraction of parent drug excreted in urine; NR = not reported; Tiss = steady-state volume of distribution. (table 1) . Meropenem is primarily excreted in the urine, with negligible fecal excretion [19] . About 70% of meropenem is cleared via the kidneys, with the remainder of the drug being cleared by metabolism to the ring-open lactam [19] . Both meropenem and its microbiologically inactive metabolite are excreted via the kidneys [39] . Pharmacokinetic studies have shown that 65%-79% of the drug [18-23, 32, 33, 39] is excreted as meropenem and 19%-27% [19, 22, 23] is excreted as the ring-open lactam.
Several studies have found that meropenem is eliminated by active tubular secretion [18, 19, 24, [31] [32] [33] 39] . For example, Bax et al. [20] found that when probenecid and meropenem were given together, meropenem clearance was reduced from 201 to 129 mL/min (a rate approximating the glomerular filtration rate). This finding suggests that there is active tubular secretion of meropenem, negligible protein binding, and no tubular reabsorption. The investigators concluded that coadministration of meropenem with drugs that compete for tubular secretion is not likely to greatly elevate plasma meropenem concentrations: the Cmax of meropenem was 48.7 mg/L, while that of meropenem/probenecid was 56.5 mg/L. However, a substantial difference between the AUC values (55% increase) was found. Table 3 . Parameters of meropenem pharmacokinetics in patients with renal impairment after a 30-minute iv infusion of 500 mg. Renal function (mL/min)/ dosing recommendation [32] Cl NOTE. AUC = area under the curve; C max maximal concentration of drug; Cl" = creatinine clearance; Cl. = renal clearance; C1 T = total plasma meropenem clearance; CT = collection time of urine sample; fe = fraction of parent drug excreted in urine; GFR glomerular filtration rate; NR not reported; V s , = steady-state volume of distribution. NOTE. Data are from [39] . AUC = area under the curve; Cmax = maximal concentration of drug; Cl, renal clearance; Cl, = total plasma meropenem clearance; fe fraction of parent drug excreted in urine in 8 h; Vss = steady-state volume of distribution.
The recovery of meropenem after intermittent dosing is similar to the recovery after continuous infusion. Mouton and Michel [27] found that large variations between subjects seem to prevail in the recovery of meropenem in the urine. This variation can be due to the extent of renal metabolism of meropenem.
Disease States
The pharmacokinetics of meropenem have been examined in patients with intraabdominal infections (table 2) as well as in patients with hepatic or renal dysfunction. Bedikian et al. [40] found a larger volume of distribution of meropenem in patients with intraabdominal infections than had been previously observed in healthy volunteers. They attributed the change in the volume of distribution to physiological changes, specifically third spacing secondary to surgery or an inflammatory response to infection. They also found a decrease in Cmax and AUC0-, an increase in mean residence time (MRT) and total plasma meropenem clearance (CL T), and no change in renal clearance (Cir.) or the elimination rate constant as compared with the parameters for healthy subjects. Despite these changes, the investigators concluded that a dosing interval of every 8 hours remained sufficient to provide therapeutic serum levels in patients with intraabdominal infections.
In patients with severe intraabdominal sepsis requiring surgical intervention, Lovering et al. [41] found that the half-life of meropenem was significantly longer than that described in healthy volunteers (table 2) . However, the investigators postulated that this difference was more likely a function of age (and associated age-related decline in renal function) rather than a result of sepsis or surgery, and they concluded that dosage adjustments were not warranted for patients with severe abdominal sepsis.
When meropenem was given to patients with liver disease [42] , no significant differences between the pharmacokinetics of meropenem or its metabolite were found when compared with observations in healthy volunteers. Furthermore, no accumulation of the drug or the metabolite was observed.
However, this report may not be representative of the wide spectrum of hepatic impairment observed in general practice. Thyrum et al. included patients with stable chronic alcoholic cirrhosis. Judging from their entry and exclusionary criteria, these patients probably had Child-Pugh Class A cirrhosis. Such limited impairment would not likely lead to significantly impaired drug metabolism. While the investigators suggested that dosage adjustments are not necessary for patients with alcoholic cirrhosis, this may not be the case for patients with more advanced impairment, such as Child-Pugh -Class B or C cirrhosis.
Several studies have examined the effect of renal impairment on the pharmacokinetics of meropenem [32] [33] [34] 43] . As shown in table 3, these studies revealed an increase in the elimination half-life of both meropenem and its metabolite with increasing renal impairment. Both C1 T and Cl, of meropenem were found to be linearly related to creatinine clearance (C1,), thus allowing the investigators to make dosing recommendations based on the patient's renal function. Nonrenal elimination of meropenem also increased as renal function decreased. Both meropenem and its metabolite were readily removed by hemodialysis; thus, an additional dose at the end of each session of hemodialysis is required [32] [33] [34] 43] . Although the Cmax [44] . Cl, = renal clearance; Cl 7. = total plasma meropenem clearance; fe = fraction of parent drug excreted in urine in 12 h; Vss = steady-state volume of distribution.
seemed to increase in patients with a Cl, of < 10 mL/min in two studies [32, 34] , in one study [33] , no changes in the Cm.x in any subject were observed.
The steady-state volume of distribution seems to remain the same in all subjects regardless of renal function [32] [33] [34] . For patients with normal renal function (C1,, >50 mL/min), the standard meropenem dosage is 1 g every 8 hours. For patients with moderately impaired renal function (C1,, 25-50 mL/min), a prolonged dosing interval is recommended (1 g every 12 hours). For patients with severe renal impairment (C1, mL/min), the reginien should be 0.5 g every 24 hours.
In the geriatric population (age, 67-80 years), Ljungberg and Nilsson-Ehle [39] found reductions in C1 T, Clr, and nonrenal clearance that led to significant increases in half-life, MRT, and AUC for both meropenem and its inactive metabolite (table  4) . Volume of distribution, urinary recovery, and Cmax remained unchanged. The investigators concluded that dosage reductions should be considered for elderly patients secondary to the physiological decline in renal function and the possible decline in metabolic capacity.
To define the profile of meropenem pharmacokinetics in children with infection, Blumer et al. [44] studied children in four age groups (2-5 months, 6-23 months, 2-5 years, and 6-12 years) who received doses of 10 to 40 mg/kg (table 5). They found no age-or dose-dependent effects on pharmacokinetics. In addition, there were no differences in the pharmacokinetic parameters when their estimates were compared with previously published data for adults. On the basis of these results, the investigators recommended a dosage regimen of 20 mg/kg every 8 hours for children and infants.
Conclusion
Meropenem is a carbapenem antibiotic with pharmacokinetic parameters similar to those for imipenem/cilastatin. Since meropenem is highly stable against renal DHP-I and has a correspondingly low nephrotoxic potential, it can be given alone without a dehydropeptidase inhibitor .such as cilastatin. It appears that meropenem can be used clinically without dosage adjustments for patients with various disease states as long as their renal function is intact. However, dosage adjustments are indicated for patients with renal insufficiency.
